Loading...

Ansell

ASX:ANN
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANN
ASX
A$3B
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
ANN Share Price and Events
7 Day Returns
0.3%
ASX:ANN
3.4%
AU Medical Equipment
0.7%
AU Market
1 Year Returns
2.6%
ASX:ANN
-3.4%
AU Medical Equipment
4.7%
AU Market
ANN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ansell (ANN) 0.3% 4% 13.9% 2.6% 32.8% 46.3%
AU Medical Equipment 3.4% 0.5% 0.7% -3.4% 39.3% 105.3%
AU Market 0.7% 1.1% 6.5% 4.7% 17.5% 4.9%
1 Year Return vs Industry and Market
  • ANN outperformed the Medical Equipment industry which returned -3.4% over the past year.
  • ANN underperformed the Market in Australia which returned 4.7% over the past year.
Price Volatility
ANN
Industry
5yr Volatility vs Market

ANN Value

 Is Ansell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ansell to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ansell.

ASX:ANN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:ANN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.929 (1 + (1- 30%) (22.69%))
1.051
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.051 * 5.96%)
8.58%

Discounted Cash Flow Calculation for ASX:ANN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ansell is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:ANN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.58%)
2019 121.53 Analyst x2 111.94
2020 127.37 Analyst x3 108.04
2021 144.04 Analyst x2 112.54
2022 160.09 Analyst x1 115.19
2023 171.92 Est @ 7.39% 113.94
2024 182.01 Est @ 5.87% 111.10
2025 190.75 Est @ 4.8% 107.23
2026 198.48 Est @ 4.05% 102.77
2027 205.49 Est @ 3.53% 97.99
2028 211.99 Est @ 3.17% 93.11
Present value of next 10 years cash flows $1,073.85
ASX:ANN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $211.99 × (1 + 2.31%) ÷ (8.58% – 2.31%)
$3,462.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,462.79 ÷ (1 + 8.58%)10
$1,520.91
ASX:ANN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,073.85 + $1,520.91
$2,594.76
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,594.76 / 127.93
$20.28
ASX:ANN Discount to Share Price
Calculation Result
Exchange Rate USD/AUD
(Reporting currency to currency of ASX:ANN)
1.399
Value per Share
(AUD)
= Value per Share in USD x Exchange Rate (USD/AUD)
= $20.28 x 1.399
A$28.37
Value per share (AUD) From above. A$28.37
Current discount Discount to share price of A$26.34
= -1 x (A$26.34 - A$28.37) / A$28.37
7.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ansell is available for.
Intrinsic value
7%
Share price is A$26.34 vs Future cash flow value of A$28.37
Current Discount Checks
For Ansell to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ansell's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Ansell's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ansell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ansell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ANN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.80
ASX:ANN Share Price ** ASX (2019-04-18) in AUD A$26.34
ASX:ANN Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.715 $18.83
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ansell.

ASX:ANN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ANN Share Price ÷ EPS (both in USD)

= 18.83 ÷ 0.80

23.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ansell is good value based on earnings compared to the AU Medical Equipment industry average.
  • Ansell is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Ansell's expected growth come at a high price?
Raw Data
ASX:ANN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 23.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
11.8%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

ASX:ANN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 23.65x ÷ 11.8%

2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ansell is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Ansell's assets?
Raw Data
ASX:ANN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $10.19
ASX:ANN Share Price * ASX (2019-04-18) in AUD A$26.34
ASX:ANN Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.715 $18.83
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.73x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:ANN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ANN Share Price ÷ Book Value per Share (both in USD)

= 18.83 ÷ 10.19

1.85x

* Primary Listing of Ansell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ansell is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Ansell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Ansell has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ANN Future Performance

 How is Ansell expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ansell expected to grow at an attractive rate?
  • Ansell's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Ansell's earnings growth is expected to exceed the Australia market average.
  • Ansell's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:ANN Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:ANN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 11.8%
ASX:ANN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 3.9%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ANN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ANN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 1,708 225 179 1
2021-06-30 1,662 207 160 8
2020-06-30 1,606 196 148 10
2019-06-30 1,537 186 127 10
ASX:ANN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,493 172 112
2018-09-30 1,491 163 125
2018-06-30 1,490 154 139
2018-03-31 1,461 172 135
2017-12-31 1,433 190 132
2017-09-30 1,404 203 125
2017-06-30 1,375 216 119
2016-12-31 1,232 231 121
2016-09-30 1,292 232 129
2016-06-30 1,353 232 137
2016-03-31 1,578 212 164

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ansell's earnings are expected to grow by 11.8% yearly, however this is not considered high growth (20% yearly).
  • Ansell's revenue is expected to grow by 3.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ANN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Ansell Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ANN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 1.30 1.30 1.30 1.00
2021-06-30 1.24 1.36 1.15 6.00
2020-06-30 1.12 1.24 0.97 7.00
2019-06-30 0.95 1.11 0.69 7.00
ASX:ANN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.80
2018-09-30 0.88
2018-06-30 0.96
2018-03-31 0.93
2017-12-31 0.90
2017-09-30 0.85
2017-06-30 0.80
2016-12-31 0.81
2016-09-30 0.86
2016-06-30 0.91
2016-03-31 1.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ansell is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ansell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ansell has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ANN Past Performance

  How has Ansell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ansell's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ansell's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Ansell's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Ansell's 1-year earnings growth is negative, it can't be compared to the AU Medical Equipment industry average.
Earnings and Revenue History
Ansell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ansell Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ANN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,492.90 111.80 377.80
2018-09-30 1,491.35 125.25 383.70
2018-06-30 1,489.80 138.70 389.60
2018-03-31 1,461.25 135.20 386.80
2017-12-31 1,432.70 131.70 384.00
2017-09-30 1,403.60 125.20 373.70
2017-06-30 1,374.50 118.70 363.40
2016-12-31 1,232.00 121.00 283.20
2016-09-30 1,292.40 129.10 301.20
2016-06-30 1,352.80 137.20 319.20
2016-03-31 1,577.70 164.25 411.55
2015-12-31 1,582.60 169.40 413.50
2015-09-30 1,613.85 178.45 427.10
2015-06-30 1,645.10 187.50 440.70
2015-03-31 1,689.50 125.70 461.40
2014-12-31 1,733.90 63.90 482.10
2014-09-30 1,662.05 52.85 470.30
2014-06-30 1,590.20 41.80 458.50
2014-03-31 1,507.35 94.75 443.40
2013-12-31 1,424.50 147.70 428.30
2013-09-30 1,398.65 143.45 418.55
2013-06-30 1,372.80 139.20 408.80
2013-03-31 1,347.12 133.70 396.77
2012-12-31 1,296.24 124.69 383.60
2012-09-30 1,279.98 129.77 373.74
2012-06-30 1,247.04 133.07 359.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ansell has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ansell used its assets less efficiently than the AU Medical Equipment industry average last year based on Return on Assets.
  • Ansell's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Ansell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ansell has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ANN Health

 How is Ansell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ansell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ansell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ansell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ansell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ansell Company Filings, last reported 3 months ago.

ASX:ANN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,362.80 546.60 414.90
2018-09-30 1,362.80 546.60 414.90
2018-06-30 1,550.20 552.00 582.80
2018-03-31 1,550.20 552.00 582.80
2017-12-31 1,562.90 564.60 597.60
2017-09-30 1,562.90 564.60 597.60
2017-06-30 1,228.70 720.50 316.60
2016-12-31 1,150.90 659.10 248.20
2016-09-30 1,150.90 659.10 248.20
2016-06-30 1,136.70 691.60 272.70
2016-03-31 1,136.70 691.60 272.70
2015-12-31 1,110.30 745.20 258.10
2015-09-30 1,110.30 745.20 258.10
2015-06-30 1,166.60 741.10 281.40
2015-03-31 1,166.60 741.10 281.40
2014-12-31 1,144.80 675.40 266.30
2014-09-30 1,144.80 675.40 266.30
2014-06-30 1,140.50 734.80 324.20
2014-03-31 1,140.50 734.80 324.20
2013-12-31 1,137.10 830.30 906.40
2013-09-30 1,137.10 830.30 906.40
2013-06-30 773.50 540.80 309.90
2013-03-31 867.34 606.30 344.63
2012-12-31 779.84 540.93 339.93
2012-09-30 779.35 540.60 339.71
2012-06-30 737.81 308.00 253.13
  • Ansell's level of debt (40.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (72.9% vs 40.1% today).
  • Debt is well covered by operating cash flow (31.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 26x coverage).
X
Financial health checks
We assess Ansell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ansell has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ANN Dividends

 What is Ansell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.43%
Current annual income from Ansell dividends. Estimated to be 2.86% next year.
If you bought A$2,000 of Ansell shares you are expected to receive A$49 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Ansell's pays a lower dividend yield than the bottom 25% of dividend payers in Australia (2.5%).
  • Ansell's dividend is below the markets top 25% of dividend payers in Australia (5.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ANN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:ANN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 0.57 1.00
2021-06-30 0.58 9.00
2020-06-30 0.55 11.00
2019-06-30 0.50 11.00
ASX:ANN Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-02-18 0.458 2.542
2018-08-20 0.455 2.684
2018-02-12 0.443 2.204
2017-08-14 0.440 2.400
2017-02-13 0.438 2.495
2016-08-15 0.435 2.506
2015-08-10 0.430 3.055
2015-02-11 0.342 1.810
2014-08-18 0.390 2.202
2013-08-28 0.331 1.967
2013-02-19 0.325 2.144
2012-08-14 0.361 2.253
2012-02-08 0.329 2.412
2011-08-15 0.311 2.345
2011-02-09 0.309 2.296
2010-08-23 0.268 2.302
2010-02-16 0.237 2.320
2009-08-17 0.230 2.751
2009-04-20 0.193 3.177

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Ansell's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.7x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.3x coverage).
X
Income/ dividend checks
We assess Ansell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ansell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ansell has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ANN Management

 What is the CEO of Ansell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Magnus Nicolin
COMPENSATION $5,205,727
AGE 61
TENURE AS CEO 9.1 years
CEO Bio

Mr. Magnus R. Nicolin, BA (Stockholm), MBA (Wharton), has been the Chief Executive Officer and Managing Director of Ansell Limited since March 1, 2010. Mr. Nicolin served as the President of Europe, Middle East, Africa and Asia Pacific at Newell Rubbermaid Inc. from January 1, 2007 to December 31, 2009 and was responsible for its European Office Products. He served as the President of Europe Operations at Newell Rubbermaid Inc. since January 1, 2007 and served as its Consultant in the Fine Writing business from May 2006 to August 2006 and President of Sanford Brands Europe from September 2006 to December 2006. He served as Executive Vice President and Chief Operating Officer at Esselte Business Systems Inc. from 1999 to 2001 and served as its President and Chief Executive Officer from 2002 to 2005, Executive Vice President of Global Marketing and Research and Development from 1998 to 1999. He served as President and Chief Executive Officer of Esselte UK Ltd. since July 2002. Mr. Nicolin served as the President and Chief Executive Officer of Esselte Office Products. He served as Group Vice President of Business Development and M&A at Pitney Bowes Inc. from 1995 to 1998. He served as Group Vice President and General Manager at Pitney Bowes Incoming Message Solutions. He served as Vice President and General Manager of Bayer Diagnostics from 1992 to 1995. He served with Strategic Planning Associates Inc., Credit Lyonnais and McKinsey & Co. Mr. Nicolin has been a Director of Ansell Limited, since March 1, 2010. He has been a Director of Primix Solutions Inc., since October 2000. He is Non-Executive Director of FAM AB. Mr. Nicolin served as a Lieutenant in the Swedish Marines for three years and attending the Swedish Naval Academy. Mr. Nicolin holds BA from Stockholm School of Economics and MBA from Wharton School from University of Pennsylvania.

CEO Compensation
  • Magnus's compensation has increased by more than 20% in the past year.
  • Magnus's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Ansell management team in years:

5.5
Average Tenure
  • The average tenure for the Ansell management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Magnus Nicolin

TITLE
MD, CEO & Executive Director
COMPENSATION
$5M
AGE
61
TENURE
9.1 yrs

Neil Salmon

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
49
TENURE
5.8 yrs

Steve Genzer

TITLE
President of IGBU
COMPENSATION
$1M
TENURE
3.6 yrs

Joe Kubicek

TITLE
President of HGBU
COMPENSATION
$1M
TENURE
1.5 yrs

John Marsden

TITLE
Senior VP of Global Operations

Giri Peddinti

TITLE
Senior VP & Global Chief Information Officer
TENURE
7.3 yrs

Jocelyn Petersen

TITLE
Vice President of Global FP&A

Mike Gilleece

TITLE
Senior VP & Corporate General Counsel
TENURE
1.8 yrs

Debbie Lynch

TITLE
Chief Human Resources Officer
TENURE
5.2 yrs

Peter Dobbelsteijn

TITLE
Senior Vice President of Global Supply Chain
COMPENSATION
$1M
TENURE
8.7 yrs
Board of Directors Tenure

Average tenure and age of the Ansell board of directors in years:

5
Average Tenure
61
Average Age
  • The tenure for the Ansell board of directors is about average.
Board of Directors

Glenn Lawrence Barnes

TITLE
Chairman
COMPENSATION
$335K
AGE
71
TENURE
6.5 yrs

Magnus Nicolin

TITLE
MD, CEO & Executive Director
COMPENSATION
$5M
AGE
61
TENURE
9.1 yrs

John Bevan

TITLE
Deputy Chairman
COMPENSATION
$175K
AGE
61
TENURE
2.2 yrs

William Day

TITLE
Independent Non-Executive Director
COMPENSATION
$174K
AGE
68
TENURE
11.7 yrs

Marissa Peterson

TITLE
Independent Non-Executive Director
COMPENSATION
$174K
AGE
56
TENURE
12.7 yrs

Leslie Desjardins

TITLE
Independent Non-Executive Director
COMPENSATION
$156K
AGE
58
TENURE
3.4 yrs

Bill Reilly

TITLE
Non-Executive Director
COMPENSATION
$108K
AGE
66
TENURE
1.5 yrs

Christina Stercken

TITLE
Independent Non-Executive Director
COMPENSATION
$117K
AGE
60
TENURE
1.5 yrs

Christine Yan

TITLE
Independent Non-Executive Director
AGE
52
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
08. Apr 19 Sell BlackRock, Inc. Company 17. Jul 18 04. Apr 19 -1,438,025 A$29.00 A$-68,939
08. Apr 19 Buy BlackRock, Inc. Company 17. Jul 18 04. Apr 19 2,252,573 A$29.03 A$236,622
21. Feb 19 Sell Vinva Investment Management Company 19. Oct 18 19. Feb 19 -2,123,533 A$22.93 A$-48,691,201
21. Feb 19 Buy Vinva Investment Management Company 19. Oct 18 19. Feb 19 3,326,730 A$24.31 A$80,865,273
31. Jan 19 Sell Nikko Asset Management Co., Ltd. Company 20. Dec 18 25. Jan 19 -1,270,434 A$23.39 A$-29,710,434
31. Jan 19 Buy Nikko Asset Management Co., Ltd. Company 20. Dec 18 25. Jan 19 5,333 A$21.79 A$116,223
07. Jan 19 Buy Christina Stercken Individual 31. Dec 18 31. Dec 18 148 A$22.27 A$3,296
21. Dec 18 Buy Nikko Asset Management Co., Ltd. Company 19. Aug 18 19. Dec 18 1,550,895 A$25.02 A$36,958,978
07. Nov 18 Buy Christina Stercken Individual 06. Nov 18 06. Nov 18 500 A$23.13 A$11,565
30. Oct 18 Sell The Vanguard Group, Inc. Company 27. Jun 18 25. Oct 18 -43,878 A$29.04 A$-1,232,207
30. Oct 18 Buy The Vanguard Group, Inc. Company 03. Jul 18 26. Oct 18 251,502 A$29.56 A$7,339,432
02. Oct 18 Sell Vinva Investment Management Company 21. Sep 18 28. Sep 18 -138,620 A$25.34 A$-3,512,732
02. Oct 18 Buy Vinva Investment Management Company 21. Sep 18 28. Sep 18 3,671 A$25.48 A$93,544
24. Sep 18 Sell Vinva Investment Management Company 20. May 18 20. Sep 18 -285,455 A$27.39 A$-7,817,572
24. Sep 18 Buy Vinva Investment Management Company 20. May 18 20. Sep 18 419,037 A$25.40 A$10,644,269
20. Sep 18 Sell Magnus Nicolin Individual 12. Sep 18 12. Sep 18 -59,008 A$25.25 A$-1,490,161
18. Jul 18 Sell BlackRock, Inc. Company 17. Aug 17 06. Jul 18 -2,199,278 A$27.71 A$-110,784
18. Jul 18 Buy BlackRock, Inc. Company 17. Aug 17 11. Jul 18 761,005 A$27.35 A$157,870
24. May 18 Sell Yarra Funds Management Limited Company 07. Feb 18 22. May 18 -822,175 A$26.59 A$-21,863,414
22. May 18 Sell Vinva Investment Management Company 21. Apr 18 18. May 18 -84,594 A$26.30 A$-2,224,452
22. May 18 Buy Vinva Investment Management Company 21. Apr 18 18. May 18 27,432 A$26.58 A$729,106
24. Apr 18 Sell Vinva Investment Management Company 04. Apr 18 20. Apr 18 -7,548 A$25.24 A$-190,482
24. Apr 18 Buy Vinva Investment Management Company 04. Apr 18 20. Apr 18 12,968 A$25.59 A$331,817
X
Management checks
We assess Ansell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ansell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ANN News

Simply Wall St News

What Does Ansell Limited's (ASX:ANN) Balance Sheet Tell Us About It?

While small-cap stocks, such as Ansell Limited (ASX:ANN) with its market cap of AU$3.4b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Understanding the company's financial health becomes. … Let's work through some financial health checks you may wish to consider if you're interested in this stock.

Simply Wall St -

What Are Analysts Saying About Ansell Limited's (ASX:ANN) Future?

Since Ansell Limited (ASX:ANN) released its earnings in December 2018,. … with earnings expected to grow by 21% in the upcoming year … the past 5-year average growth rate of 4.6%

Simply Wall St -

If You Had Bought Ansell (ASX:ANN) Shares Three Years Ago You'd Have Made 45%

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … This means it's unlikely the market is judging the company based on earnings growth.

Simply Wall St -

What Investors Should Know About Ansell Limited's (ASX:ANN) Financial Strength

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Ansell Limited (ASX:ANN), with a market cap of AU$3.2b, are often out of the spotlight. … However, history shows that overlooked mid-cap companies have performed better on a risk-adjusted manner than the smaller and larger segment of the market. … ANN’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns.

Simply Wall St -

Do You Know What Ansell Limited's (ASX:ANN) P/E Ratio Means?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … Price to Earnings Ratio = Share Price (in reporting currency) ÷ Earnings per Share (EPS) … P/E of 22.29 = $17.75 (Note: this is the share price in the reporting currency, namely, USD ) ÷ $0.80

Simply Wall St -

Does Ansell Limited (ASX:ANN) Have A Place In Your Portfolio?

A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. … Historically, Ansell Limited (ASX:ANN) has paid a dividend to shareholders. … Let's dig deeper into whether Ansell should have a place in your portfolio.

Simply Wall St -

Ansell Limited (ASX:ANN) Has A ROE Of 9.1%

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every A$1 worth of shareholders' equity, it generated A$0.091 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Why Fundamental Investors Might Love Ansell Limited (ASX:ANN)

In the case of Ansell Limited (ASX:ANN), there's. … that has been able to sustain great financial health over the past … For those interested in digger a bit deeper into my commentary,

Simply Wall St -

With 17% Earnings Growth, Did Ansell Limited (ASX:ANN) Outperform The Industry?

How Did ANN's Recent Performance Stack Up Against Its Past. … Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of 4.1%, indicating the rate at which ANN is growing has accelerated … What's the driver of this growth?

Simply Wall St -

Does Ansell Limited (ASX:ANN) Have A Good P/E Ratio?

Ansell has a price to earnings ratio of 17.41, based on the last twelve months. … Price to Earnings Ratio = Price per Share (in the reporting currency) ÷ Earnings per Share (EPS) … P/E of 17.41 = $16.79 (Note: this is the share price in the reporting currency, namely, USD ) ÷ $0.96

Simply Wall St -

ANN Company Info

Description

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates through two segments, Healthcare and Industrial. The Healthcare segment offers a range of surgical and examination gloves covering various applications; and healthcare safety devices and active infection protection products for healthcare patients. This segment’s products include medical exam gloves, general disposable gloves, surgical gloves, event protection and sharps safety products, O.R. turnover solutions, patient positioners, staff and patient ergonomics, silver barrier dressings, outer dressings, medical specialty gloves, safety essentials, and fluid and trip management products, as well as burn and wound care products. It also distributes single use gloves used in industrial applications, including chemical, food services, life sciences, electronics, and automotive aftermarket. This segment offers its products under the Microflex, SANDEL, MICROTOUCH, GAMMEX, ENCORE, ANSELL MEDICAL, MEDI-GRIP, TouchNTuff, and Marigold brands for acute care hospitals, emergency services, alternate care, and dentistry and veterinary clinics. The Industrial segment provides hand, foot, and body protection solutions for industrial worker environments and specialty applications, including the automotive, chemical, food processing, life sciences, machinery and equipment, metal fabrication, mining, and oil and gas industries. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1888 and is based in Richmond, Australia.

Details
Name: Ansell Limited
ANN
Exchange: ASX
Founded: 1888
A$3,369,681,204
127,930,190
Website: http://www.ansell.com
Address: Ansell Limited
678 Victoria Street,
Level 3,
Richmond,
Victoria, 3121,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ANN Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
OTCPK ANSL.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB PD1A Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA ANN Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
OTCPK ANSL.Y UNSPONSORED ADR Pink Sheets LLC US USD 09. Oct 2007
Number of employees
Current staff
Staff numbers
12,482
Ansell employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 10:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/17
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.